- Home
- BBIO vs SEIC Comparison
BBIO vs SEIC Comparison
Compare BBIO & SEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- SEIC
- Stock Information
- Founded
- BBIO 2015
- SEIC 1968
- Country
- BBIO United States
- SEIC United States
- Employees
- BBIO N/A
- SEIC N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- SEIC Investment Bankers/Brokers/Service
- Sector
- BBIO Health Care
- SEIC Finance
- Exchange
- BBIO Nasdaq
- SEIC Nasdaq
- Market Cap
- BBIO 10.4B
- SEIC 10.6B
- IPO Year
- BBIO 2019
- SEIC N/A
- Fundamental
- Price
- BBIO $66.62
- SEIC $80.61
- Analyst Decision
- BBIO Strong Buy
- SEIC Buy
- Analyst Count
- BBIO 16
- SEIC 7
- Target Price
- BBIO $65.88
- SEIC $100.29
- AVG Volume (30 Days)
- BBIO 2.2M
- SEIC 737.8K
- Earning Date
- BBIO 10-29-2025
- SEIC 10-22-2025
- Dividend Yield
- BBIO N/A
- SEIC 1.20%
- EPS Growth
- BBIO N/A
- SEIC 30.75
- EPS
- BBIO N/A
- SEIC 5.43
- Revenue
- BBIO $235,812,000.00
- SEIC $2,246,646,000.00
- Revenue This Year
- BBIO $115.12
- SEIC $10.06
- Revenue Next Year
- BBIO $65.29
- SEIC $7.82
- P/E Ratio
- BBIO N/A
- SEIC $15.08
- Revenue Growth
- BBIO 7.62
- SEIC 9.44
- 52 Week Low
- BBIO $21.72
- SEIC $64.66
- 52 Week High
- BBIO $65.00
- SEIC $93.96
- Technical
- Relative Strength Index (RSI)
- BBIO 77.10
- SEIC 40.16
- Support Level
- BBIO $52.75
- SEIC $78.34
- Resistance Level
- BBIO $65.00
- SEIC $83.87
- Average True Range (ATR)
- BBIO 2.34
- SEIC 1.70
- MACD
- BBIO 1.00
- SEIC 0.08
- Stochastic Oscillator
- BBIO 80.66
- SEIC 44.97
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About SEIC SEI Investments Company
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.